Price Target Update on Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) : 18 Wall Street analysts covering Teva Pharmaceutical Industries Limited (NYSE:TEVA) believe that the average level the stock could reach for the short term is $74.3. The maximum price target given is $100 and the minimum target for short term is around $58, hence the standard deviation is calculated at $9.29.

Other Equity analysts have also commented on the company shares. Credit Suisse initiates coverage on Teva Pharmaceutical Industries Limited (NYSE:TEVA) The current rating of the shares is Neutral. Equity Analysts at the Firm announces the price target to $60 per share. The rating by the firm was issued on May 4, 2016.

Teva Pharmaceutical Industries Limited (NYSE:TEVA): stock turned positive on Thursday. Though the stock opened at $51.7, the bulls momentum made the stock top out at $51.71 level for the day. The stock recorded a low of $51.05 and closed the trading day at $51.37, in the green by 0.35%. The total traded volume for the day was 4,642,733. The stock had closed at $51.19 in the previous days trading.

The company shares have dropped -13.21% from its 1 Year high price. On Jul 28, 2015, the shares registered one year high at $72.31 and the one year low was seen on May 12, 2016. The 50-Day Moving Average price is $52.28 and the 200 Day Moving Average price is recorded at $57.42.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.